Jubilant Organosys, an integrated pharmaceutical industry player, has notified that its Bangalore-based subsidiary Jubilant Biosys Ltd, has entered into a drug discovery partnership with BioLeap, LLC, USA.
Under the relationship, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform.
Cambridge Solutions Limited has informed that its wholly owned subsidiary, Cambridge Integrated Services Group has entered into a significant new contract with Compagnie Pour Assistance Technique et Investissements S. A. (CATISA), to provide consulting services, business development and procurement services over the next two years.
The contract has a value of up to US$15 million over this period.
Rate two-way but falls through more stops to make a bottom under monthly support; 50 bar MA failed to offer solid support. Cross-liquidation continues. Rally likely bids absorb offers under the 1.3300 area.
Sovereign offers seen into the highs last week traders say but those may be covering into the dip this week. Aggressive liquidation by EURO-Sterling cross spreaders providing the main selling. Technical levels around the 1.3300 area are firm; look for a solid bounce from here.
Rate continued lower into next support level before a "dead cat bounce". No sign yet of the bottom firmly in after failing to hold the 1.4500 handle during the day. Cross-spreaders continue to sell GBP across the board.
2008 lows likely target but sellers are drying up in my view as volumes have been light on this break. Spillover from EURO likely but action still technical. Bears took a stand above the 1.5250 area last week; likely they will look to cover into significant lows-look for two-way action into this bottom.